Teva-Handok's Calcitoninene-related peptide (CGRP) targeted migraine treatment Ajovy has been covered by insurance benefits since January, and it will fight for prescription leadership with Emgality of Lily Korea, which was listed in September last year. The two drugs are in the same family, but there are differences in usage dosage, so choices are being made according to the characteristics of patients with severe migraines. Emgality is a method of administering 240 mg (two consecutive subcutaneous injections of 120 mg each) once, and subcutaneous injections of 120 mg once a month after that. In the case of Ajovy, 225 mg once a month or 675 mg (3 consecutive 225 mg) once every three months is used by subcutaneous inj